Preservative use in topical glaucoma medications

Area of Science:

• Ophthalmology
• Pharmacology

Background:

• Benzalkonium chloride (BAK) is the primary preservative in topical ocular hypotensive medications.
• Concerns exist regarding the long-term safety of BAK despite its widespread use.

Purpose of the Study:

• To systematically review preclinical and clinical data on Benzalkonium chloride (BAK) safety in glaucoma patients.
• To assess the clinical relevance of reported BAK toxicity.

Main Methods:

• Systematic literature review of preclinical (in vitro, in vivo) and clinical studies.
• Analysis of BAK concentrations and exposure durations in relation to physiological conditions.

Main Results:

• Most preclinical studies showed negative effects, but often used higher BAK concentrations and exposure times than typical patient use.
• Dedicated clinical investigations did not consistently show BAK-related toxicity.
• Current evidence supports the general safety of BAK for glaucoma treatment.

Conclusions:

• Benzalkonium chloride (BAK) is generally safe for most glaucoma patients.
• Subpopulations with impaired tear film may benefit from preservative-free options or alternative preservatives.
• Further research is needed to identify at-risk patient groups.